We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Drug Designed To Treat Cataracts Shows Promise in Lab Tests


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Drug Designed To Treat Cataracts Shows Promise in Lab Tests"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

ARU expert leads work on anti-cataract drug, which has positive results in lab tests


A revolutionary new treatment for cataract has shown extremely positive results in laboratory tests, giving hope that the condition, that currently can only be cured with surgery, could soon be treated with drugs.


The results have been published today in the peer-reviewed journal Investigative Ophthalmology and Visual Science.


Cataract is a clouding of the eye lens that develops over time and affects the quality of vision. It is caused by a disorganisation of the proteins in the lens that leads to clumps of protein forming that scatter light and severely reduce transmission to the retina. Cataracts cause vision loss and blindness for millions of people worldwide.


A team of international scientists, led by Professor Barbara Pierscionek, Deputy Dean (Research and Innovation) in the Faculty of Health, Education, Medicine and Social Care at Anglia Ruskin University (ARU), have been carrying out advanced optical tests on an oxysterol compound that had been proposed as an anti-cataract drug.


In laboratory trials, treatment with the oxysterol compound VP1-001 showed an improvement in refractive index profiles – a key optical parameter that is needed to maintain high focusing capacity – in 61% of lenses. This means that the protein organisation of the lens is being restored, resulting in the lens being better able to focus. This was supported by a reduction in lens opacity in 46% of cases.


Professor Pierscionek, who is also a member of the Medical Technology Research Centre at Anglia Ruskin University (ARU), said:


“This study has shown the positive effects of a compound that had been proposed as an anti-cataract drug but never before tested on the optics of the lens. It is the first research of this kind in the world.


“It has shown that there is a remarkable difference and improvement in optics between eyes with the same type of cataract that were treated with the compound compared to those that were not.


“Improvements occurred in some types of cataract but not in all indicating that this may be a treatment for specific cataracts. This suggests distinctions may need to be made between cataract types when developing anti-cataract medications. It is a significant step forward towards treating this extremely common condition with drugs rather than surgery.”


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement